We use cookies for a better user experience. Read our Privacy Policy

I Agree

Tyrosine Kinase Inhibitors Market

Tyrosine Kinase Inhibitors Market (Product - BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors, Other Tyrosine Kinase Inhibitors; Application - Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer; Distribution Channel - Hospital Pharmacies, Independent Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Tyrosine Kinase Inhibitors Market - Snapshot

The global tyrosine kinase inhibitors market is expanding owing to high prevalence and increase in incidence of cancer across the globe. The global tyrosine kinase inhibitors market was valued at more than US$ 18.0 Bn in 2017 and is projected to surpass US$ 19.0 Bn by 2026, expanding at a negative compound annual growth rate (CAGR) during the forecast period. The global market is witnessing expansion at a relatively higher growth rate owing to increasing expenditure on health care and high prevalence and increase in incidence of cancer across the globe.

tyrosine kinase inhibitors market

Cancer is the unregulated growth of body cells due to genetic mutations in its differentiation regulatory genes. Tyrosine kinases are enzymes that signal the cell differentiation cycle, mutation in their expression genes leads to their over expression, which results in uncontrolled proliferation of cells to form tumors. Tyrosine kinase inhibitors are small molecules that bind to the receptor site of the kinase enzyme available at cell surface. This binding blocks the phosphorylation by blocking adenosine tri-phosphate (ATP) biding to the receptor. Based on type of kinase receptors being targeted, tyrosine kinase inhibitors can be classified into BCR-ABL TKIs, EGFR TKIs, VEGFR TKIs, Janus Kinase Inhibitors, BTK inhibitors.

Tyrosine kinase inhibitors (TKIs) aid patients suffering from different cancer diseases. Tyrosine kinase inhibitors were accepted largely due to specificity and efficacy and the benefits these offer over chemotherapy and radiotherapy. High prevalence and incidence rates of cancer diseases such as chronic myeloid leukemia (CML), lung cancer, breast cancer, and renal cell cancer, and expanding indications of existing and pipeline on TKIs have expanded the indication areas of existing and pipeline on tyrosine kinase inhibitors in order to address various unmet needs and extend the product lifecycle. These factors, collectively, are projected to drive the global tyrosine kinase inhibitors market in the near future. Furthermore, rise in awareness about cancer diagnosis and treatment and surge in adoption in underdeveloped and developing markets are key factors that are estimated to fuel the tyrosine kinase inhibitors market in the near future.

The global tyrosine kinase inhibitors market has been broadly segmented based on product, application, distribution channel, and region. In terms of product, the global market has been classified into BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor (VEGFR) tyrosine kinase inhibitors, and other tyrosine kinase inhibitors. BCR-ABL tyrosine kinase inhibitors were one of the first approved TKIs for cancer treatment. Their wide acceptance and indications have contributed to their significant share in the global market. VEGFR tyrosine kinase inhibitors are projected to be a highly promising class of TKIs. Several companies have developed their VEGFR TKIs drugs with features of multi kinase receptor inhibition. These factors are likely to augment the segment by the end of 2026. In terms of application, lung cancer is the leading cause of cancer deaths in the world. TKIs such as EGFR, ALK, and HGFR have been in use for treating lung cancers. Increase in incidence of lung cancer is likely to propel the segment.

In terms of distribution channel, the global tyrosine kinase inhibitors market has been segregated into hospital pharmacies, independent pharmacies, and online pharmacies. The hospital pharmacies segment is projected to account for a prominent share of the market. International and regional pharmacy service providers are expanding their operations across the regions, this is attributed to strong infrastructure network for distribution, thereby contributing to the dominant share held by the independent pharmacies segment of the global tyrosine kinase inhibitors market. Consolidation among independent pharmacies and their expanding operations across regions are likely to propel the independent pharmacies segment in the global market. Increase in adoption of e-commerce and convenience offered by online pharmacies are expected to drive the adoption of online pharmacies in developed markets.

In terms of region, the global tyrosine kinase inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market; however, it is projected to gain market share by the end of 2026. The market in North America is primarily driven by the high cost of TKIs and high health care expenditure, which have contributed to the leading share held by North America. Furthermore, demand for advanced treatment options such as targeted therapies has contributed to the leading share held by the region. Recent patent expiry of several blockbuster TKIs has negatively impacted the market in North America. However, the introduction of new TKIs, such as JAK TKIs, multi-targeted TKIs, ALT TKIs, and others has compensated for the impact, which is projected to fuel the TKIs market in North America during the forecast period. The tyrosine kinase inhibitors market in Asia Pacific is projected to expand at a rapid pace during the forecast period. Rest of Asia Pacific countries dominated the tyrosine kinase inhibitors market in Asia Pacific, while the market in China and India is estimated to expand at a significant CAGR during the forecast period.

Companies such as Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Johnson & Johnson accounted for a major share of the global tyrosine kinase inhibitors market in 2017. In May 2018, Pfizer's XALKORI (crizotinib) received FDA breakthrough therapy designation in two new indications. This is expected to increase the company's therapy segment research in the near future. Other global players operating in the market include AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., , Eisai Co., Ltd., and Eurofarma Laboratórios S/A, who are focused on strategic acquisitions and collaborations with parallel companies in order to improve and strengthen their geographic presence in the international market.

Presently, commercially available tyrosine kinase inhibitors are indicated for treating non-small cell lung cancer, renal cell cancer, breast cancer, chronic myeloid leukemia, hepatocellular carcinoma, and breast cancer. These drugs are indicated as monotherapy or combination therapy, along with chemotherapy or as post-surgical resection remedy. However, tyrosine kinase inhibitors are not available for other cancer types such as neuroendocrine tumors.

According to the National Cancer Institute of the U.S., around 1,735,350 new cancer cases were diagnosed in the U.S. in 2018. Moreover, the U.S. had 15.5 million cancer survivors in 2016, which is projected to increase to 20.3 million by 2026.

Surge in Adoption in Underdeveloped and Developing Markets

  • Awareness about cancer diagnosis and treatment is being spread across the globe. Governing bodies are taking initiatives to provide access to healthcare to public at large.
  • Easing of norms for drug import, initiatives to attract health care providers & pharmaceutical companies to establish their base, and drug pricing regulations are likely to drive the oncology market. This, in turn, is projected to augment the tyrosine kinase inhibitors market.
  • Availability of generics in underdeveloped and developing markets is anticipated to spur adoption of tyrosine kinase inhibitors

Global tyrosine kinase inhibitors market has been segmented as given below:

By Product

  • BCR-ABL Tyrosine Kinase Inhibitors
  • Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
  • Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
  • Other Tyrosine Kinase Inhibitors (Janus Kinase Inhibitors, Bruton’s Kinase Inhibitor, HGFR TKIs, ALK / ROS1 TKIs, etc.)

By Application

  • Chronic Myeloid Leukemia (CML)
  • Lung Cancer
  • Breast Cancer
  • Renal Cell Cancer
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Independent Pharmacies
  • Online Pharmacies

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East
    • Saudi Arabia
    • UAE
    • Rest of Middle East
  • Africa
    • South Africa
    • Rest of Africa
Tyrosine Kinase Inhibitors Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Tyrosine Kinase Inhibitors Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunity
            4.3.4. Key Trends
     4.4. Global Tyrosine Kinase Inhibitors Market Analysis and Forecasts, 2016–2026
     4.4.1. Market Revenue Projections (US$ Mn)

5. Global Tyrosine Kinase Inhibitors Market Outlook
     5.1. Key Brand / Product Analysis
     5.2. Patent & Market Exclusivity Analysis
     5.3. Overview of Approved Indications
     5.4. Tyrosine Kinase Inhibitors - Clinical Trial Analysis
     5.5. Recent Industry Developments
     5.6. Pipeline Analysis
     5.7. Key Mergers & Acquisitions

6. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Product 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
            6.3.1. BCR-ABL Tyrosine Kinase Inhibitors
            6.3.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
            6.3.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
            6.3.4. Other Tyrosine Kinase Inhibitors
     6.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Product

7. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Application 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
            7.3.1. Chronic Myeloid Leukemia (CML)
            7.3.2. Lung Cancer
            7.3.3. Breast Cancer
            7.3.4. Renal Cell Cancer
            7.3.5. Others 
     7.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Application

8. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Distribution Channel 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
            8.3.1. Hospital Pharmacies
            8.3.2. Independent Pharmacies
            8.3.3. Online Pharmacies
     8.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Distribution Channel

9. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Global Tyrosine Kinase Inhibitors Market Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East &Africa 
     9.3. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Country/Region

10. North America Tyrosine Kinase Inhibitors Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. North America Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
            10.2.1. BCR-ABL Tyrosine Kinase Inhibitors
            10.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
            10.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
            10.2.4. Other Tyrosine Kinase Inhibitors
     10.3. North America Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
            10.3.1. Chronic Myeloid Leukemia (CML)
            10.3.2. Lung Cancer
            10.3.3. Breast Cancer
            10.3.4. Renal Cell Cancer
            10.3.5. Others 
     10.4. North America Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
            10.4.1. Hospital Pharmacies
            10.4.2. Independent Pharmacies
            10.4.3. Online Pharmacies
     10.5. North America Tyrosine Kinase Inhibitors Market Forecast, by Country, 2016–2026
            10.5.1. U.S.
            10.5.2. Canada
     10.6. North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis 
            10.6.1. By Product 
            10.6.2. By Application 
            10.6.3. By Distribution Channel 
            10.6.4. By Country

11. Europe Tyrosine Kinase Inhibitors Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2. Europe Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
            11.2.1. BCR-ABL Tyrosine Kinase Inhibitors
            11.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
            11.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
            11.2.4. Other Tyrosine Kinase Inhibitors
     11.3. Europe Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
            11.3.1. Chronic Myeloid Leukemia (CML)
            11.3.2. Lung Cancer
            11.3.3. Breast Cancer
            11.3.4. Renal Cell Cancer
            11.3.5. Others 
     11.4. Europe Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
            11.4.1. Hospital Pharmacies
            11.4.2. Independent Pharmacies
            11.4.3. Online Pharmacies
     11.5. Europe Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. U.K.
            11.5.3. France
            11.5.4. Spain
            11.5.5. Italy
            11.5.6. Rest of Europe
     11.6. Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis 
            11.6.1. By Product 
            11.6.2. By Application 
            11.6.3. By Distribution Channel
            11.6.4. By Country

12. Asia Pacific Tyrosine Kinase Inhibitors Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
            12.2.1. BCR-ABL Tyrosine Kinase Inhibitors
            12.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
            12.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
            12.2.4. Other Tyrosine Kinase Inhibitors
     12.3. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
            12.3.1. Chronic Myeloid Leukemia (CML)
            12.3.2. Lung Cancer
            12.3.3. Breast Cancer
            12.3.4. Renal Cell Cancer
            12.3.5. Others 
     12.4. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
            12.4.1. Hospital Pharmacies
            12.4.2. Independent Pharmacies
            12.4.3. Online Pharmacies
     12.5.Market Forecast, by Country, 2016–2026
            12.5.1. China
            12.5.2. Japan
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis 
            12.6.1. By Product 
            12.6.2. By Application 
            12.6.3. By Distribution Channel 
            12.6.4. By Country

13. Latin America Tyrosine Kinase Inhibitors Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
            13.2.1. BCR-ABL Tyrosine Kinase Inhibitors
            13.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
            13.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
            13.2.4. Other Tyrosine Kinase Inhibitors
     13.3. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
            13.3.1. Chronic Myeloid Leukemia (CML)
            13.3.2. Lung Cancer
            13.3.3. Breast Cancer
            13.3.4. Renal Cell Cancer
            13.3.5. Others 
     13.4. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
            13.4.1. Hospital Pharmacies
            13.4.2. Independent Pharmacies
            13.4.3. Online Pharmacies
     13.5. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis 
            13.6.1. By Product 
            13.6.2. By Application 
            13.6.3. By Distribution Channel 
            13.6.4. By Country

14. Middle East Tyrosine Kinase Inhibitors Market Analysis and Forecast
     14.1.Introduction
            14.1.1. Key Findings
     14.2. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
            14.2.1. BCR-ABL Tyrosine Kinase Inhibitors
            14.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
            14.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
            14.2.4. Other Tyrosine Kinase Inhibitors
     14.3. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
            14.3.1. Chronic Myeloid Leukemia (CML)
            14.3.2. Lung Cancer
            14.3.3. Breast Cancer
            14.3.4. Renal Cell Cancer
            14.3.5. Others 
     14.4. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
            14.4.1. Hospital Pharmacies
            14.4.2. Independent Pharmacies
            14.4.3. Online Pharmacies
     14.5. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-regions, 2016–2026
            14.5.1. UAE
            14.5.2. Saudi Arabia
            14.5.3. Rest of Middle East & Africa
     14.6. Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis 
            14.6.1. By Product 
            14.6.2. By Application 
            14.6.3. By Distribution Channel 
            14.6.4. By Country

15. Africa Tyrosine Kinase Inhibitors Market Analysis and Forecast
     15.1.Introduction
            15.1.1. Key Findings
     15.2. Africa Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
            15.2.1. BCR-ABL Tyrosine Kinase Inhibitors
            15.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
            15.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
            15.2.4. Other Tyrosine Kinase Inhibitors
     15.3. Africa Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
            15.3.1. Chronic Myeloid Leukemia (CML)
            15.3.2. Lung Cancer
            15.3.3. Breast Cancer
            15.3.4. Renal Cell Cancer
            15.3.5. Others 
     15.4. Africa Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
            15.4.1. Hospital Pharmacies
            15.4.2. Independent Pharmacies
            15.4.3. Online Pharmacies
     15.5. Africa Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-regions, 2016–2026
            15.5.1. South Africa
            15.5.2. Rest of Africa
     15.6. Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis 
            15.6.1. By Product 
            15.6.2. By Application 
            15.6.3. By Distribution Channel

16. Competition Landscape
     16.1.Market Player – Competition Matrix (By Tier and Size of companies)
     16.2.Global Tyrosine Kinase Inhibitors Market Snapshot of Companies (2017)
     16.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            16.3.1. AstraZeneca Plc
                     16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.1.2. Product Portfolio
                     16.3.1.3. SWOT Analysis
                     16.3.1.4. Strategic Overview
            16.3.2. Pfizer, Inc.
                     16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.2.2. Product Portfolio
                     16.3.2.3. SWOT Analysis
                     16.3.2.4. Strategic Overview
            16.3.3. Novartis AG
                     16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.3.2. Product Portfolio
                     16.3.3.3. SWOT Analysis
                     16.3.3.4. Strategic Overview
            16.3.4. Bristol-Myers Squibb Company
                     16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.4.2. Product Portfolio
                     16.3.4.3. SWOT Analysis
                     16.3.4.4. Strategic Overview
            16.3.5. Bayer AG
                     16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.5.2. Product Portfolio
                     16.3.5.3. SWOT Analysis
                     16.3.5.4. Strategic Overview
            16.3.6. Boehringer Ingelheim International GmbH
                     16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.6.2. Product Portfolio
                     16.3.6.3. SWOT Analysis
                     16.3.6.4. Strategic Overview
                     16.3.6.5. Financial
            16.3.7. F. Hoffmann-La Roche Ltd.
                     16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.7.2. Product Portfolio
                     16.3.7.3. SWOT Analysis
                     16.3.7.4. Strategic Overview
            16.3.8. Johnson & Johnson
                     16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.8.2. Product Portfolio
                     16.3.8.3. SWOT Analysis
                     16.3.8.4. Strategic Overview
            16.3.9. Eisai Co., Ltd.
                     16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.9.2. Product Portfolio
                     16.3.9.3. SWOT Analysis
                     16.3.9.4. Strategic Overview
            16.3.10. Eurofarma Laboratórios S/A
                     16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.10.2. Product Portfolio
                     16.3.10.3. SWOT Analysis
                     16.3.10.4. Strategic Overview

List of Tables

Table 01: Global BCR-ABL Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 02: Global EGFR Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 03: Global VEGFR Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 04: Global Other Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 05: Patent & Market Exclusivity Overview, by Molecule (1/4)
Table 06: Patent & Market Exclusivity Overview, by Molecule (2/4)
Table 07: Patent & Market Exclusivity Overview, by Molecule (3/4)
Table 08: Patent & Market Exclusivity Overview, by Molecule (4/4)
Table 09: Overview of Indications Approved, by Molecule (1/8)
Table 10: Overview of Indications Approved, by Molecule (2/8)
Table 11: Overview of Indications Approved, by Molecule (3/8)
Table 12: Overview of Indications Approved, by Molecule (4/8)
Table 13: Overview of Indications Approved, by Molecule (5/8)
Table 14: Overview of Indications Approved, by Molecule (6/8)
Table 15: Overview of Indications Approved, by Molecule (7/8)
Table 16: Overview of Indications Approved, by Molecule (8/8)
Table 17: BCR-ABL Tyrosine Kinase Inhibitors Pipeline Analysis (1/2)
Table 18: BCR-ABL Tyrosine Kinase Inhibitors Pipeline Analysis (2/2)
Table 19: EGFR Tyrosine Kinase Inhibitors Pipeline Analysis
Table 20: VEGFR Tyrosine Kinase Inhibitors Pipeline Analysis (1/3)
Table 21: VEGFR Tyrosine Kinase Inhibitors Pipeline Analysis (2/3)
Table 22: VEGFR Tyrosine Kinase Inhibitors Pipeline Analysis (3/3)
Table 23: Multi-target Tyrosine Kinase Inhibitors Pipeline Analysis 
Table 24: Bruton’s Tyrosine Kinase Inhibitors Pipeline Analysis (1/2)
Table 25: Bruton’s Tyrosine Kinase Inhibitors Pipeline Analysis (2/2)
Table 26: Aurora Tyrosine Kinase Inhibitors Pipeline Analysis
Table 27: Other Tyrosine Kinase Inhibitors Pipeline Analysis (1/3)
Table 28: Other Tyrosine Kinase Inhibitors Pipeline Analysis (2/3)
Table 29: Other Tyrosine Kinase Inhibitors Pipeline Analysis (3/3)
Table 30: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 31: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 32: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 33: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 34: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 35: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 36: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 37: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 38: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 39: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 40: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 41: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 42: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 43: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 44: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 45: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 46: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 47: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 48: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 49: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 50: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 51: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 52: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 53: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 54: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Product, 2016–2026
Table 55: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2016–2026
Table 56: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures

Figure 01: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 03: Global Tyrosine Kinase Inhibitors Market Value Share, by Product Type (2017)
Figure 04: Global Tyrosine Kinase Inhibitors Market Value Share, by Application (2017)
Figure 05: Global Tyrosine Kinase Inhibitors Market Value Share, by Distribution Channel (2017)
Figure 06: Global Tyrosine Kinase Inhibitors Market Value Share, by Region (2017)
Figure 07: Clinical Trial Analysis by Phase
Figure 08: Clinical Trial Analysis by Status
Figure 09: Clinical Trial Analysis by Completion  and Termination Rate
Figure 10: Clinical Trial Analysis by Region
Figure 11: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 12: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by BCR-ABL TKIs, 2016–2026
Figure 13: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by EGFR TKIs, 2016–2026
Figure 14: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by VEGFR TKIs, 2016–2026
Figure 15: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth, by Other TKIs, 2016–2026
Figure 16: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 17: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 18: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by CML, 2016–2026
Figure 19: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lung Cancer, 2016–2026
Figure 20: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Renal Cell Cancer, 2016–2026
Figure 21: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2016–2026
Figure 22: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016–2026
Figure 23: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018–2026
Figure 24: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 25: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2016–2026
Figure 26: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Independent Pharmacies, 2016–2026
Figure 27: Global Tyrosine Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016–2026
Figure 28: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018–2026
Figure 29: Global Tyrosine Kinase Inhibitors Market Value Share Analysis, by Region/Country, 2017 and 2026
Figure 30: Global Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Region/Country, 2018–2026
Figure 31: North America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 32: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 33: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 34: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 35: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018?2026
Figure 36: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 37: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018?2026
Figure 38: North America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country, 2017 and 2026
Figure 39: North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country, 2018–2026
Figure 40: Europe Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 41: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 42: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 43: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 44: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018?2026
Figure 45: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 46: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018?2026
Figure 47: Europe Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 48: Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 49: Asia Pacific Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 50: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 51: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 52: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 53: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018?2026
Figure 54: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 55: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2018?2026
Figure 56: Asia Pacific Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 57: Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 58: Latin America Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 59: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 60: Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 61: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 62: Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018 -2026
Figure 63: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 64: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 65: Latin America Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 66: Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 67: Middle East Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 68: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 69: Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 70: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 71: Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018 -2026
Figure 72: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 73: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 - 2026
Figure 74: Middle East Tyrosine Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 75: Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 76: Africa Tyrosine Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 77: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Product, 2017 and 2026
Figure 78: Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Product, 2018–2026
Figure 79: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Application, 2017 and 2026
Figure 80: Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis, by Application, 2018?2026
Figure 81: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2017 and 2026
Figure 82: Africa Tyrosine Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018?2026
Figure 83: Global Tyrosine Kinase Inhibitors Market Share, by Company, 2017

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

376

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved